

# **Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method**

---

## **Guidance for Industry**

Additional copies of this guidance are available from the Office of Communication, Outreach and Development (OCOD), Center for Biologics Evaluation and Research, Food and Drug Administration, Phone: 800-835-4709 or 240-402-8010, Email: [industry.biologics@fda.hhs.gov](mailto:industry.biologics@fda.hhs.gov), or from the Internet at <https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances>.

For questions on the content of this guidance, contact OCOD at the phone numbers or email address listed above.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Biologics Evaluation and Research  
September 2026**

**Contains Nonbinding Recommendations**

**TABLE OF CONTENTS**

|             |                                     |          |
|-------------|-------------------------------------|----------|
| <b>I.</b>   | <b>INTRODUCTION.....</b>            | <b>1</b> |
| <b>II.</b>  | <b>BACKGROUND .....</b>             | <b>1</b> |
| <b>III.</b> | <b>RECOMMENDATIONS.....</b>         | <b>2</b> |
| <b>IV.</b>  | <b>COMMUNICATION WITH FDA .....</b> | <b>6</b> |
| <b>V.</b>   | <b>REFERENCES.....</b>              | <b>7</b> |
|             | <b>APPENDIX.....</b>                | <b>8</b> |

# **Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method**

---

## **Guidance for Industry**

*This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.*

### **I. INTRODUCTION**

The purpose of this guidance is to provide recommendations on the development of blood collection, processing, and storage systems (e.g., blood bags with anticoagulant and additive solutions, empty bags for platelet pooling) intended for the manufacture of blood and blood components for transfusion using the buffy coat (BC) method and on regulatory submissions to Food and Drug Administration (FDA) for such products. This guidance is intended for manufacturers of blood collection, processing, and storage systems. The recommendations in this guidance do not apply to devices used to manufacture platelet rich plasma or similar products used for therapeutic purposes other than transfusion. The recommendations also do not apply to blood establishments that intend to manufacture blood and blood components using the BC method with approved or cleared collection, processing, and storage systems.

In general, FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

### **II. BACKGROUND**

Whole Blood (WB)-derived components for transfusion, including platelets, plasma, and red blood cells (RBCs), can be manufactured using methods that consist of different, sequential centrifugation steps. In the United States (U.S.), blood establishments currently prepare WB-derived blood components using the platelet rich plasma (PRP) method (Ref. 1). In this method, WB is centrifuged at a relatively low speed (i.e., a "soft spin") to yield RBCs and PRP. PRP is then separated from the RBCs, and the PRP undergoes a second centrifugation step (i.e., a "hard spin") to yield platelet and plasma components. Certain other countries prepare blood

## **Contains Nonbinding Recommendations**

components from WB using the BC method (Ref. 2). In the BC method, WB is centrifuged at a high speed (i.e., a “hard spin”) to yield RBCs, plasma and a zone between the RBCs and plasma, which is the BC that contains platelets and white blood cells. The BC is then separated from the RBCs and plasma. Either a single BC or a pool of 4-6 BCs is then centrifuged at low speed (i.e., a “soft spin”) to yield the supernatant-containing platelets which are separated, often leukoreduced, and then stored in plasma or additive solution, under defined conditions and duration before transfusion.

Blood establishments in the U.S. are interested in using the BC method to manufacture blood components for transfusion. Studies demonstrate that blood components prepared by using the BC method are comparable to blood components prepared using the PRP method, in terms of biochemical and physiological characteristics (Refs. 3-7). In addition, use of the BC method may offer logistical advantages, which could result in higher plasma and platelet recovery and increased platelet availability, when compared to the PRP method (Ref. 8).

Blood and blood components must be prepared in a manner consistent with the instructions provided by the manufacturer (Title 21 Code of Federal Regulations (CFR) 606.65(e)), including the directions provided in the instructions for use of the approved or cleared collection, processing, and storage system. To prepare blood components using the BC method, blood establishments must use blood collection, processing and storage systems approved or cleared for such use.

This guidance provides recommendations to manufacturers who wish to obtain FDA approval or clearance to market blood collection, processing, and storage systems intended for the manufacture of blood components for transfusion using the BC method. With the availability of such FDA-approved or cleared systems, blood establishments in the U.S. would have the option of manufacturing WB-derived blood components using the BC method and licensed blood establishments could submit biologics license application (BLA) supplements to FDA.

### **III. RECOMMENDATIONS**

Our recommendations for the development of blood collection, processing, and storage systems for the manufacture of blood components for transfusion using the BC method are as follows:

1. The regulatory pathway for a blood collection, processing, and storage system depends on whether the system consists of an empty bag alone or a bag that contains anticoagulant or storage solutions. Manufacturers should contact FDA to clarify the appropriate regulatory pathway (e.g., New Drug Application (NDA), Premarket Approval (PMA) or 510(k), Investigational New Drug (IND) or Investigational Device Exemption (IDE) submission) for their blood collection, processing, and storage systems. We encourage manufacturers to contact FDA to discuss their planned submission and supporting data and information (see recommendation 4, below).
2. We recognize that manufacturers of blood collection, processing, and storage systems are increasingly transitioning to systems that do not contain di(2-ethylhexyl) phthalate

## **Contains Nonbinding Recommendations**

(DEHP) and that the transition to such materials may also require changes to storage and additive solutions. We support efforts to develop blood collection, processing, and storage systems that do not contain DEHP and the introduction of additive solutions that are currently not approved by FDA and we encourage manufacturers to contact FDA to discuss their supporting data and planned submissions.

3. FDA recognizes that that some blood collection, processing, and storage systems entail holding Whole Blood for up to 24 hours before separation (overnight hold). Note that FDA regulations at 21 CFR 640.4(h) for Whole Blood, 21 CFR 640.16(a) for red blood cells, 21 CFR 640.24(b) for platelets, and 21 CFR 640.34(a) and 21 CFR 640.34(c) for plasma do not restrict the timeframe for separation of the component from Whole Blood. Rather, the timeframe for separation must be as specified in the directions for use of the blood collection, processing and storage system. Manufacturers should include data that supports the timeframe for separation from Whole Blood (e.g., 4, 8, 24 hours) using the BC method.
4. Regulatory submissions for blood collection, processing, and storage systems should include the following information:
  - a. The design of the collection, processing, and storage system, including materials used for construction.
  - b. A description of the established methods, facilities and controls used for the manufacture of the blood collection, processing and storage system.
  - c. Biocompatibility studies and toxicologic risk assessments:

Biocompatibility testing should be performed on the sterilized finished product, using test conditions simulating clinical use. Biocompatibility tests should include extractables and leachable studies and a toxicological risk assessment of these chemicals. Manufacturers may refer to the latest version of the International Standard ISO 10993-1 (Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process), and applicable FDA guidance documents including “Use of International Standard ISO 10993-1, ‘Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process’; Guidance for Industry and FDA Staff,” dated September 2023 (Ref. 9).
  - d. Performance data that support sterility of the collection, processing and storage system including sterilization validation, endotoxin testing, and container closure integrity evaluation.
  - e. Performance data that support maximum shelf life of the collection, processing, and storage system.

## Contains Nonbinding Recommendations

- f. Results of studies evaluating the quality of blood components prepared using the BC method throughout the duration of storage.

The study results should demonstrate that blood components prepared using the BC method are comparable to blood components prepared using approved or cleared collection, processing, and storage systems. If the collection, processing, and storage system includes pooling of BC to prepare platelets, study results should represent the maximum pool size.

Manufacturers should conduct in vitro studies that evaluate key parameters representing the quality of blood components prepared with their collection, processing and storage systems developed for the BC method. This includes parameters tested as a primary endpoint and other parameters as secondary endpoints. Some suggested parameters for the secondary endpoints for platelets, plasma and RBC components to demonstrate comparability with blood components prepared in approved or cleared blood collection, processing and storage systems are listed in the Appendix. While the list is not comprehensive nor exhaustive, we view these measurements or some combination thereof as an adequate demonstration of the quality of the blood components for transfusion.

Manufacturers should use standard summary statistics (e.g., mean, standard deviation, minimum, median, and maximum values) to report the results of the in vitro studies. Study acceptance criteria for each blood component type should include the following:

- i. Platelet components (evaluated for single units or pools):
  - Primary endpoints:
    - Platelet pH at end of storage: 95% confidence that greater than 95% of components have a pH  $\geq 6.2$  (22°C).
    - Platelet yield at end of storage: 95% confidence that greater than 75% of components have a platelet yield of  $\geq 5.5 \times 10^{10}$  platelets per unit or  $3.0 \times 10^{11}$  for pooled BC platelet units.
  - Secondary endpoints at end of storage: The averages of the differences between test and control should be less than 20%.
    - The control arm should include platelets that are manufactured using approved or cleared collection, processing, and storage systems. Manufacturers should justify selection of a control platelet product or the use of historical control data in their submission.

## Contains Nonbinding Recommendations

- We recommend a sample size of at least 60 single units or 60 pools in the test and control arms. Manufacturers may propose an alternative, statistically sound sample size and supporting data in their submission.

### ii. Plasma components:

Biochemical and functional parameters of plasma components manufactured using BC method should be compared to control plasma after at least 30 days of frozen storage. We recommend a sample size of at least 60 units in the test and control arms. The averages of the differences between test and control should be less than 20%.

### iii. RBC components:

- Primary endpoint: We recommend using 95% confidence that more than 95% of components show  $\leq 1.0\%$  hemolysis at the end of storage.
  - We recognize that donor-related factors may result in variable degrees of hemolysis and potential failure to meet the acceptance criteria. Failures during testing should be investigated and described in the submission. FDA will consider the reason for the failure (e.g., donor-related factors), if identified, during our review of the submission.
- Secondary endpoints at the end of storage: We recommend a sample size of at least 60 units in the test and control arms. The averages of the differences between test and control should be less than 20%.

g. If the collection, processing, and storage system includes a leukocyte reduction filter, you should provide results on the performance of the leukoreduction filter. We recommend the following acceptance criteria:

- i. Residual white blood cell (WBC) content: 95% confidence that greater than 95% of RBC components have  $< 5.0 \times 10^6$  residual WBCs. For platelet units:  $< 8.3 \times 10^5$  residual WBCs or  $< 5.0 \times 10^6$  residual WBCs for a platelet pool.
- ii. Percent recovery of the original component: The acceptance criteria for RBC or platelets is at least an 85 percent recovery of the original component.

h. Manufacturers should conduct appropriate clinical studies or submit existing clinical data to demonstrate the safety and efficacy of blood components prepared using the BC method.

## **Contains Nonbinding Recommendations**

### **IV. COMMUNICATION WITH FDA**

We recommend manufacturers engage CBER's Office of Blood Research and Review (OBRR) early in product development and before submission of a drug or device application. The meeting type for such discussions depends on the regulatory pathway and the stage of product development. These include pre-submission meetings for devices or type C meetings for NDAs. Contact OBRR with any questions regarding the appropriate meeting type.

## Contains Nonbinding Recommendations

### V. REFERENCES

1. Gulliksson H. Platelets from platelet-rich-plasma versus buffy-coat-derived platelets: what is the difference? *Rev Bras Hematol Hemoter*. 2012; 34: 76–77.
2. van der Meer PF, Reesink HW, deKorte D, Loos, JA, Klei TRL. The history of buffy coat platelet concentrate: The Dutch Story. *Vox Sang*. 2022; 117:913-919.
3. Lu FQ, Kang W, Peng Y, Wang WM. Characterization of blood components separated from donated whole blood after an overnight holding at room temperature with the buffy coat method. *Transfusion* 2011; 51: 2199-2207.
4. Levin E, Jenkins C, Culibrk B, Gyöngyössi-Issa MI, Serrano K, Devine DV. Development of a quality monitoring program for platelet components: a report of the first four years' experience at Canadian Blood Services. *Transfusion*. 2012; 52: 810-818.
5. Cerelli E, Nocera M, Bartolomeo ED, Panzani P, Baricchi R. Effect of adhesive properties of buffy coat on the quality of blood components produced with Top & Top and Top & Bottom bags. *Blood Transfusion* 2015; 13:265-273.
6. Philip J, Samantha K, Chatterjee T, Biswas AK, Mallhi RS. Evaluation of random donor platelets produced from buffy coat stored for 24 h at ambient temperature: Should this be implemented in India? *Indian J Hematol Blood Transfus*. 2015; 31 :264-268.
7. Beshkar P, Hosseini E, Ghasemzadeh M. Superior integrin activating capacity and higher adhesion to fibrinogen matrix in buffy coat-derived platelet concentrates (PCs) compared to PRP-PCs. *Transfus Apher Sci*. 2018; 57:76-81.
8. Gammon RR , Devine D, Katz LM, Quinly E, Wu Y, Rowe K, Razatos A, Min K, Reichenberg S, Smith R. Buffy coat platelets coming to America: Are we ready? *Transfusion*. 2021; 61:627-633.
9. FDA Guidance for Industry and Food and Drug Administration Staff. Use of International Standard ISO 10993-1, “Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process,” September 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and>

## Contains Nonbinding Recommendations

### APPENDIX

**Recommended in-vitro parameters for evaluation of platelets, plasma and RBC components at the end of storage.**

#### 1. Platelets

| Item | In-vitro Parameters                                         |
|------|-------------------------------------------------------------|
| 1    | Mean platelet volume (MPV)                                  |
| 2    | Glucose *                                                   |
| 3    | Lactate *                                                   |
| 4    | pO <sub>2</sub>                                             |
| 5    | pCO <sub>2</sub>                                            |
| 6    | Bicarbonate (HCO <sub>3</sub> <sup>-</sup> ), extracellular |
| 7    | Lactate dehydrogenase (LDH)*                                |
| 8    | Morphology score                                            |
| 9    | Hypotonic stress response (HSR)                             |
| 10   | Extent of platelets shape change (ESC)                      |
| 11   | CD62P                                                       |
| 12   | PS exposure by annexin V binding or lactadherin             |

You should report the parameters shown with “\*” as normalized values to the platelet content for glucose and lactate. For LDH, normalize the result to total cellular LDH content thus calculate relative LDH release.

#### 2. Plasma

| Item | In-vitro Parameters              |
|------|----------------------------------|
| 1    | Total protein                    |
| 2    | Albumin                          |
| 3    | IgG                              |
| 4    | Fibrinogen                       |
| 5    | PT                               |
| 6    | APTT                             |
| 7    | Prothrombin fragment 1,2 (PF1,2) |
| 8    | Factor V activity                |
| 9    | Factor VII activity              |
| 10   | Factor VIII activity             |
| 11   | Factor IX activity               |
| 12   | Factor X activity                |
| 13   | Factor XI activity               |
| 14   | Protein C                        |
| 15   | Protein S                        |
| 16   | ADAMTS 13 activity               |
| 17   | vWF:Ag and activity              |
| 18   | Alpha 2-antiplasmin activity     |

## Contains Nonbinding Recommendations

### 3. RBCs

| Item | In-vitro Parameters                        |
|------|--------------------------------------------|
| 1    | pH                                         |
| 2    | pO <sub>2</sub>                            |
| 3    | pCO <sub>2</sub>                           |
| 4    | HCO <sub>3</sub> <sup>-</sup>              |
| 5    | ATP conc. *                                |
| 6    | Sodium (Na <sup>+</sup> ), extracellular   |
| 7    | Potassium (K <sup>+</sup> ), extracellular |
| 8    | Glucose                                    |
| 9    | Lactate *                                  |
| 10   | Hemoglobin conc. (Hgb)*                    |
| 11   | Hemoglobin content/unit                    |
| 12   | Mean corpuscular volume (MCV)              |
| 13   | RBC morphology score                       |
| 14   | Hematocrit                                 |

You should report the parameters shown with “\*” as normalized values to the RBC content.

### Contains Nonbinding Recommendations

| Guidance History*      | Date           | Description                                        |
|------------------------|----------------|----------------------------------------------------|
| Level 1 Final Guidance | September 2026 | See Notice of Availability for more information.** |
| Level 1 Draft Guidance | October 2024   | See Notice of Availability for more information.** |

\*This table was implemented beginning August 2026 and previous guidance history may not be captured in totality.

\*\*The Notice of Availability is accessible via the [Search for FDA Guidance Documents webpage](#).